Tonix制药控股 TNXP 深 沪
已收盘 12-19 16:00:00 美东时间
17.13
-1.080
-5.93%
华盛通- 最 高20.56
- 今 开18.31
- 成交量 50.93万股
- 最 低 13.70
- 昨 收 18.21
- 总市值 3.21亿
- 52周最高 69.9648
- 市盈率 静 --
- 换手率 2.72%
- 52周最低 0.15
- 委 比 -80.39%
- 总股本 1874.00万
- 历史最高 1318400.00
- 量 比 1.55
- 振 幅 37.67%
- 历史最低 0.1006
- 每 手 1
- 风险率 13.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Tonix Pharmaceuticals (TNXP) Stock Jumped Monday Morning
Tonix Pharmaceuticals shares are rising Monday morning after the company announced the U.S. commercial availability of its new drug, TONMYA.
11-17 23:11
Tonix Pharmaceuticals' TONMYATM Now Commercially Available Across U.S.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, announced today that TONMYATM (cyclobenzaprine HCl sublingual tablets) is now
11-17 20:10
Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors
Tonix Pharmaceuticals appoints James Hunter to its Board of Directors. Hunter brings over 40 years of experience in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab, and Novartis. He led the launch of Tonix Medicines and the acquisition of migraine assets Zembrace and Tosymra. His appointment strengthens Tonix’s commercial strategy as it prepares for the potential launch of TNX-102 SL for fibromyalgia later this year.
06-13 11:00
Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention
Tonix Pharmaceuticals的CEO Seth Lederman将于2025年6月16日在波士顿BIO大会上演讲，介绍公司专注于疼痛管理及疫苗开发，包括纤维肌痛治疗药物TNX-102 SL的最新进展。
06-10 11:00
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025
Tonix Pharmaceuticals announced a poster presentation at EULAR 2025 focusing on TNX-102 SL, a sublingual cyclobenzaprine formulation targeting fibromyalgia. The presentation, by Iredell Iglehart, M.D., highlights the drug's effects on non-restorative sleep and sustained pain reduction.
06-05 11:00
Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase
Tonix Pharmaceuticals Holding Corp. announced that its CEO, Seth Lederman, participated in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase. The company is focused on developing therapies for pain management and vaccines addressing public health challenges. Notably, TNX-102 SL, a candidate for fibromyalgia management, has received FDA’s Fast Track designation and an August 15, 2025 PDUFA goal date. Tonix also operates a state-of-the-art infectious disease research facility.
05-22 11:00
艾切托盘中异动 股价大跌6.07%报0.968美元
北京时间2025年02月08日03时22分，艾切托（ACET.us）股票出现异动，股价快速下跌6.07%。截至发稿，该股报0.968美元/股，成交量94.3475万股，换手率1.14%，振幅7.77%。 最近的财报数据显示，该股实现营业收入0.00美元，净利润-30.48百万美元，每股收益-0.34美元，毛利-1.59百万美元，市盈率-0.58倍。 机构评级方面，在所有8家参与评级的机构中，75%的券商给予买入建议，25%的券商给予持有建议，无券商给予卖出建议。 艾切托股票所在的生物技术行业中，整体跌幅为0.72%。其相关个股中，Conduit Pharmaceuticals Inc.、Sur...
02-08 03:22
康乃德生物盘中异动 大幅下挫6.67%
北京时间2025年02月08日02时57分，康乃德生物（CNTB.us）股票出现波动，股价急速下跌6.67%。截至发稿，该股报0.980美元/股，成交量524股，换手率0.00%，振幅0.00%。 最近的财报数据显示，该股实现营业收入24.12百万美元，净利润7.65百万美元，每股收益0.14美元，毛利23.64百万美元，市盈率-2.67倍。 机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。 康乃德生物股票所在的生物技术行业中，整体跌幅为0.67%。其相关个股中，Conduit Pharmaceuticals Inc.、Surrozen Inc ...
02-08 02:57
知临集团盘中异动 下午盘快速上涨8.57%
北京时间2024年12月18日03时04分，知临集团（APM.us）股票出现波动，股价急速上涨8.57%。截至发稿，该股报0.782美元/股，成交量4654股，换手率0.08%，振幅5.44%。 最近的财报数据显示，该股实现营业收入431378.00美元，净利润-2.82百万美元，每股收益-0.62美元，毛利-1.11百万美元，市盈率-1.19倍。 机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。 知临集团股票所在的生物技术行业中，整体涨幅为0.78%。其相关个股中，Portage Biotech Inc.、Klotho Neurosciences Inc C/Wts 21/06...
2024-12-18 03:04
